Pharmaceuticals
Price
$74.80
+3.24%Market Cap
$33.26B
Day High
$75.05
Day Low
$72.90
Zoetis delivered modest Q1 FY2026 revenue growth of 2.9% to $2.26B, with net income essentially flat at $601M, while long-term debt surged 73% to $9.05B, significantly pressuring stockholders' equity and leverage ratios.
Key risk: Elevated Leverage from Debt Surge
Long-term debt increased 73% YoY to $9.05B, pushing the debt-to-equity ratio to approximately 3.69x. This elevated leverage increases interest expense burden and reduces financial flexibility, particularly if operating cash flows continue to decline. A sustained drop in earnings could strain debt service capacity.
Other Pharmaceuticals companies